AbCellera Biologics

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbCellera Biologics reports robust earnings and growth opportunities ahead

AbCellera Biologics demonstrated strong financials and growth in Q4 2022, with a focus on building an engine for antibody discovery and development.
The company's strategic approach to partnerships and contract negotiations provides flexibility and potential for increased value creation.
Despite challenges in decision-making and program advancement, AbCellera's business model and liquidity position position it well for future opportunities.

AbCellera Biologics (ABCL) reports solid Q1 performance and eyes strategic growth opportunities

AbCellera Biologics (ABCL) showcases a strong performance in Q1 2023, focusing on long-term value creation and strategic partnerships.
Despite challenges in revenue streams and resource allocation, the company's emphasis on technology development and program diversity bodes well for future growth.
Opportunities lie in expanding partnerships, leveraging advancements in cancer therapy, and driving innovation in drug development for sustained success.

AbCellera reports Q2 revenue growth, faces clinical development uncertainty

AbCellera Biologics reported mixed financial results for Q2 2023, with revenue growth but a net loss due to continued investments.
The company showcased strengths in patent defense, R&D capabilities, and partnerships, while facing challenges in clinical development uncertainty and financial performance.
Opportunities lie in global therapeutics discovery, liquidity strength, and collaboration with Eli Lilly for COVID-19 antibody development, positioning AbCellera for future growth.

AbCellera reports Q3 results, advances innovative therapies and partnerships

AbCellera Biologics reported mixed financial results in Q3 2023 but demonstrated commitment to advancing innovative therapies and strategic partnerships.
Strengths lie in promising assets, financial stability, innovative molecule design, and progress on development candidates, while challenges include profitability concerns and operational complexities.
Opportunities for growth include expanding the product pipeline, exploring novel treatments through partnerships, and optimizing therapies for improved patient outcomes and market positioning.
Overall, AbCellera's performance reflects a balance of financial stability, innovation, and strategic focus, with future updates poised to drive investor interest and market impact.

AbCellera Biologics reports Q1 performance, highlights partnerships and growth

AbCellera Biologics showcased strong performance in Q1 2024, with a focus on advancing internal programs, strategic partnerships, and technological innovations.
Despite financial challenges, the company's strengths lie in its robust pipeline, strong financial position, and promising partnerships with industry leaders.
Navigating challenges in profitability and market competition, AbCellera has significant opportunities to drive growth through partnerships, technological advancements, and market expansion.

AbCellera Biologics reports Q2 revenue growth and strategic partnerships

AbCellera Biologics' Q2 2024 performance reflects a strong financial position, progress in key programs, and strategic partnerships driving future growth.
While facing challenges in profitability and research fee reductions, the company's focus on innovation and partnerships presents opportunities for market expansion.
Overall, AbCellera's emphasis on internal pipeline development and strategic collaborations positions them well for long-term success in the biologics industry.

AbCellera Biologics reports Q3 loss but poised for clinical advancements

AbCellera Biologics is navigating its transition to a clinical stage biotech with promising programs and a strong financial position.
While facing challenges in managing R&D expenses and achieving profitability, the company's strategic moves and preparedness for clinical trials bode well for future growth.
Opportunities lie in further investments in development, advancing novel therapies, and leveraging its financial strength to capitalize on emerging opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies.

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

AbCellera Biologics (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate AbCellera Biologics Inc. (ABCL) to Report a Decline in Earnings: What to Look Out for

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024.

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) will announce its first quarter 2024 financial results on Tuesday, May 7, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologic.

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

Adaptive Biotechnologies

Bitfarms Ltd

Blink Charging

Grab Holdings Ltd

Opendoor

Taboola

This month in March is a great time to pick up shares in these best penny stocks to buy. I chose the companies due to their strong fundamentals and potential for significant upside.

The 7 Best Penny Stocks to Buy in Q2 2024

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Bloom Burton Healthcare Conference on Tuesday, April 16, 2024, at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time). A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the presentation. About AbCellera Biologics Inc.

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

Biogen

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) and Biogen Inc. (Nasdaq: BIIB) have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in neuroscience. “Delivering biologics across the blood brain barrier is one of the most important and long-standing problems in neuroscience,” said Murray McCutcheon, Ph.D., SVP, Partnering at AbCellera. “We are excited to work with Bio.

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced that its scientists will present four posters with data from its T-cell engager programs and platform at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 at the San Diego Convention Center. With its T-cell engager platform, AbCellera is expanding therapeutic opportunities for this modality by generating molecules with the potential for improved efficacy and saf.

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024

Avidity Biosciences

Vir Biotechnology

Investors know that the world of biotech stocks is home to a great percentage of opportunities that can triple and quadruple their capital. It's also fairly easy to identify such stocks using screener tools that can tease out such opportunities.

3 Highly Rated Biotech Stocks to Buy for 300% Gains

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced that Peter Thiel has notified the Company of his intention to resign from the Company's Board of Directors for personal reasons, effective March 7, 2024. “AbCellera continues to expand the frontier of biotech, a nefariously difficult and vital field,” said Peter Thiel. “I am proud to have helped them with their mission.” Mr. Thiel joined AbCellera's Board of Directors in November 2020 and served as the Chairm.

AbCellera Announces Resignation of Board Member

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following investor conferences: 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024, at 11:50 a.m. Pacific Time (2:50 p.m. Eastern Time) KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Wednesday, March 20, 2024, at 8:15 a.m. Pacific Time (11:15 a.m. Eastern Time) Live audio webcasts of each presentation may be accesse.

AbCellera to Present at Upcoming Investor Conferences in March

AbCellera Biologics Inc. (ABCL) Q4 2023 Earnings Call Transcript

Although the revenue and EPS for AbCellera Biologics Inc. (ABCL) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

AbCellera Biologics Inc. (ABCL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2023. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. “In 2023 we began shifting capital allocation from building capabilities to using them, which includes advancement of our first internal programs and strategic partnerships,” said Carl Hansen, Ph.D., founder and CEO of AbCellera. “We are in the final stages of buil.

AbCellera Reports Full Year 2023 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) will announce its full year 2023 financial results on Tuesday, February 20, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biolog.

AbCellera to Report Full Year 2023 Financial Results on February 20, 2024

Cerus

Taysha Gene Therapies

Small- to mid-cap growth stocks largely struggled over the past two years. With the Federal Reserve likely to pivot on interest rates this year, this group may be poised for a trend reversal.

3 Growth Stocks That Could Go Parabolic in 2024

Here is how AbCellera Biologics Inc. (ABCL) and Bionano Genomics, Inc. (BNGO) have performed compared to their sector so far this year.

Is AbCellera Biologics (ABCL) Outperforming Other Medical Stocks This Year?

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time). A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the presentation. About AbCellera B.

AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024

Ginkgo Bioworks Holdings

Recursion Pharmaceuticals

One of the biggest stories of the year has been the rise of AI in every industry. This trend will hit biotech stocks no less than any others.

AI Meets Biotech: 3 Top Stocks Transforming Medical Science

AbCellera Biologics is a biotech company using AI-powered platforms to discover and analyze target-specific antibodies. The company emphasizes partnerships to expedite drug development and has two drugs set for IND approval in 2025. AbCellera has a strong financial position and is trading at a relatively low cash multiple, making it an attractive investment in biotech.

Buy AbCellera Biologics's Revolutionizing AI-Powered Drug Development Platform

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023.

AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023.

AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023

AbCellera Biologics Inc. (NASDAQ:ABCL ) Q3 2023 Results Conference Call November 2, 2023 5:00 PM ET Company Participants Tryn Stimart - Chief Legal & Compliance Officer Carl Hansen - President, CEO Andrew Booth - CFO Conference Call Participants Allison Bratzel - Piper Sandler Robyn Karnauskas - Truist Andrea Tan - Goldman Sachs Stephen Willey - Stifel Puneet Souda - Leerink Partners Steven Mah - Cowen Malcolm Hoffman - BMO Operator Good afternoon, and welcome to AbCellera's Third Quarter 2023 Business Update Conference Call. My name is Kate, and I will facilitate the audio portion of today's interactive broadcast.

AbCellera Biologics Inc. (ABCL) Q3 2023 Earnings Call Transcript

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q3 2023 Business Results.

AbCellera Reports Q3 2023 Business Results

WILMINGTON, Del. & VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology.

News for AbCellera Biologics Stock (ABCL)